In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Conversational AI has rapidly evolved beyond basic chatbot frameworks. However, most large language models (LLMs) still suffer from a critical limitation—they generate responses based only on static ...

There’s a lot to know about search intent, from using deep learning to infer search intent by classifying text and breaking down SERP titles using Natural Language Processing (NLP) techniques, to ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

DeepSeek AI has announced the release of DeepSeek-Prover-V2, a groundbreaking open-source large language model specifically designed for formal theorem proving within the Lean 4 environment. This ...

Add a description, image, and links to the recursive-search topic page so that developers can more easily learn about it.

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...